Publicaciones en colaboración con investigadores/as de Hospital Universitario Arnau de Vilanova (28)

2024

  1. Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023

    Neurologia, Vol. 39, Núm. 2, pp. 196-208

2023

  1. Spanish cardiac catheterization and coronary intervention registry. 32nd official report of the Interventional Cardiology Association of the Spanish Society of Cardiology (1990-2022)

    Revista Espanola de Cardiologia, Vol. 76, Núm. 12, pp. 1021-1031

2022

  1. A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma

    Blood cancer journal, Vol. 12, Núm. 4, pp. 68

  2. Evolution of RAS Mutations in Cell-Free DNA of Patients with Tissue RAS Wild-Type Metastatic Colorectal Cancer Receiving First-Line Treatment: The PERSEIDA Study

    Cancers, Vol. 14, Núm. 24

  3. External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study

    Neuroendocrinology, Vol. 112, Núm. 1, pp. 88-100

  4. Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics. A retrospective, open-label study of the PETHEMA/Spanish Myeloma Group (GEM)

    Leukemia and Lymphoma, Vol. 63, Núm. 14, pp. 3438-3447

2021

  1. Management of Psoriasis During Preconception, Pregnancy, Postpartum, and Breastfeeding: A Consensus Statement

    Actas Dermo-Sifiliograficas, Vol. 112, Núm. 3, pp. 225-241

2020

  1. Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure

    Antiviral Research, Vol. 174

  2. Psychometric Properties of the SymptoMScreen Questionnaire in a Mild Disability Population of Patients with Relapsing–Remitting Multiple Sclerosis: Quantifying the Patient’s Perspective

    Neurology and Therapy, Vol. 9, Núm. 1, pp. 173-179

2019

  1. Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 37, Núm. 28, pp. 2571-2580

2018

  1. First-line treatment in lymphomatoid papulosis: a retrospective multicentre study

    Clinical and Experimental Dermatology, Vol. 43, Núm. 2, pp. 137-143

  2. Impact of rotational coronary angiography in the amount of iodinated contrast and the exposure to ionising radiations in patients undergoing invasive coronary procedures: A systematic review and meta-analysis

    Archivos de Cardiologia de Mexico, Vol. 88, Núm. 4, pp. 277-286

  3. Large-scale external validation and comparison of prognostic models: An application to chronic obstructive pulmonary disease

    BMC Medicine, Vol. 16, Núm. 1

  4. Prospective evaluation of the development of contrast-induced nephropathy in patients with acute coronary syndrome undergoing rotational coronary angiography vs. conventional coronary angiography: CINERAMA study

    Nefrologia, Vol. 38, Núm. 2, pp. 220-221

  5. Prospective evaluation of the development of contrast-induced nephropathy in patients with acute coronary syndrome undergoing rotational coronary angiography vs. conventional coronary angiography: CINERAMA study

    Nefrologia, Vol. 38, Núm. 2, pp. 169-178

2017

  1. Ischemic strokes: Is it mandatory to rule out aortic thrombosis?

    Archivos de Cardiologia de Mexico, Vol. 87, Núm. 3, pp. 228-230

2016

  1. Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients with Cirrhosis

    Gastroenterology, Vol. 150, Núm. 5, pp. 1160-1170.e3

2015

  1. Differential effect of modified Medical Research Council Dyspnea, COPD Assessment Test, and Clinical COPD Questionnaire for symptoms evaluation within the new GOLD staging and mortality in COPD

    Chest, Vol. 148, Núm. 1, pp. 159-168

  2. Trisomy 8, a cytogenetic abnormality in myelodysplastic syndromes, is constitutional or not?

    PLoS ONE, Vol. 10, Núm. 6

  3. Variability in the prescription of non-biologic disease-modifying antirheumatic drugs for the treatment of spondyloarthritis in Spain

    Seminars in Arthritis and Rheumatism, Vol. 44, Núm. 6, pp. 633-640